Pictet Asset Management
NKTR icon

Pictet Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Pictet Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$268K Buy
+3,718
New +$212K ﹤0.01% 1775

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pictet Asset Management's NKTR Position: Q1 2026 in Review

Pictet Asset Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 3,718 shares worth $268K. The stake represents ﹤0.01% of the portfolio and ranks #1775 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Pictet Asset Management held 3,718 shares of Nektar Therapeutics worth $268K as of Q1 2026.
  • Nektar Therapeutics was a new Pictet Asset Management position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1775 holding.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.